CANCER:

Gastric Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Gastroesophageal Junction Adenocarcinoma (152)

Gastroesophageal Cancer (38)

Gastric Adenocarcinoma (35)

Gastroesophageal Junction Adenocarcinoma (152)

Gastroesophageal Cancer (38)

Gastric Adenocarcinoma (35)

›

No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week (New B) nivolumab Sensitive : A1 Int J Cancer - 1wk	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week nivolumab Sensitive : A1 Int J Cancer - 1 week - (New B)
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week (New B) nivolumab Sensitive : A1 Int J Cancer - 1wk	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week nivolumab Sensitive : A1 Int J Cancer - 1 week - (New B)
CPEB1 underexpression	Gastric Adenocarcinoma	CPEB1 underexpression	Gastric Adenocarcinoma	5-fluorouracil Sensitive: C3 – Early Trials J Gastrointest Oncol - 2 weeks (New C3) 5-fluorouracil Sensitive : C3 J Gastrointest Oncol - 2wk	5-fluorouracil Sensitive: C3 – Early Trials J Gastrointest Oncol - 2 weeks 5-fluorouracil Sensitive : C3 J Gastrointest Oncol - 2 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) fam-trastuzumab deruxtecan-nxki Sensitive : A1 ESMO 2022 - 3wk	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ESMO 2022 - 3 weeks fam-trastuzumab deruxtecan-nxki Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) fam-trastuzumab deruxtecan-nxki Sensitive : A1 ESMO 2022 - 3wk	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ESMO 2022 - 3 weeks fam-trastuzumab deruxtecan-nxki Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	KN046 + KN026 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) KN046 + KN026 Sensitive : C3 ESMO 2022 - 3wk	KN046 + KN026 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks KN046 + KN026 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	KN046 + KN026 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) KN046 + KN026 Sensitive : C3 ESMO 2022 - 3wk	KN046 + KN026 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks KN046 + KN026 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
CEACAM5 overexpression	Gastric Cancer	CEACAM5 overexpression	Gastric Cancer	SAR408701 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) SAR408701 Sensitive : C3 ESMO 2022 - 3wk	SAR408701 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks SAR408701 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	nivolumab + regorafenib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab + regorafenib Sensitive : C3 ESMO 2022 - 3wk	nivolumab + regorafenib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab + regorafenib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
ITGAM overexpression + LAG3 overexpression	Gastric Cancer	ITGAM overexpression + LAG3 overexpression	Gastric Cancer	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab Sensitive : C3 ESMO 2022 - 3wk	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
ITGAM overexpression + CTLA4 overexpression	Gastric Cancer	ITGAM overexpression + CTLA4 overexpression	Gastric Cancer	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab Sensitive : C3 ESMO 2022 - 3wk	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-1 expression	Gastroesophageal Junction Adenocarcinoma	PD-1 expression	Gastroesophageal Junction Adenocarcinoma	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C3 ESMO 2022 - 3wk	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-1 expression	Gastric Cancer	PD-1 expression	Gastric Cancer	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C3 ESMO 2022 - 3wk	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR expression + HER-2 expression	Gastric Cancer	EGFR expression + HER-2 expression	Gastric Cancer	ASLAN001 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) ASLAN001 Sensitive : C3 ESMO 2022 - 3wk	ASLAN001 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks ASLAN001 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-1 expression	Gastroesophageal Junction Adenocarcinoma	PD-1 expression	Gastroesophageal Junction Adenocarcinoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab + ipilimumab Sensitive : C3 ESMO 2022 - 3wk	nivolumab + ipilimumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab + ipilimumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
No biomarker	Gastric Adenocarcinoma	No biomarker	Gastric Adenocarcinoma	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval cisplatin + 5-fluorouracil + docetaxel Sensitive : A1	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval cisplatin + 5-fluorouracil + docetaxel Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval cisplatin + 5-fluorouracil + docetaxel Sensitive : A1	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval cisplatin + 5-fluorouracil + docetaxel Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	TPF Sensitive: A1 - Approval TPF Sensitive : A1	TPF Sensitive: A1 - Approval TPF Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	TPF Sensitive: A1 - Approval TPF Sensitive : A1	TPF Sensitive: A1 - Approval TPF Sensitive : A1
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1
HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
HER-2 negative + PD-L1 expression	Gastric Cancer	HER-2 negative + PD-L1 expression	Gastric Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	trifluridine/tipiracil Sensitive: A1 - Approval trifluridine / tipiracil Sensitive : A1	trifluridine/tipiracil Sensitive: A1 - Approval trifluridine / tipiracil Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	trifluridine/tipiracil Sensitive: A1 - Approval trifluridine / tipiracil Sensitive : A1	trifluridine/tipiracil Sensitive: A1 - Approval trifluridine / tipiracil Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1
HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1
MSI-H/dMMR	Gastric Cancer	MSI-H/dMMR	Gastric Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1

Gastric Cancer

Associations(636)

Associations
(636)